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Abstract
Introduction: Ecstasy (3,4-methylenedioxymethamphetamin), a hallucinogenic amphetamine, is often used by
young people, especially at ‘raves’. This illicit drug can cause many metabolic changes and its use, when associated
with prolonged exercise, may exacerbate ketoacidosis in type 1 diabetic patients.
Case presentation: This is a case of ketoacidosis complicated by the use of ecstasy in a 19-year-old insulin-
dependent diabetic Caucasian woman.
Conclusion: The use of ecstasy may trigger diabetic ketoacidosis in patients with a preexisting metabolic disorder
Introduction
A considerable number of young people are exposed to
3,4-methylenedioxymethamphetamine (MDMA -, also
known as ‘ecstasy’) [1], a synthetic compound with
structural and pharmacological characteristics similar to
those of amphetamines. The use of this drug has
increased considerably over the last 15 years [2]. The
drug was originally developed as an appetite suppres-
sant, although it was never promoted commercially for
that purpose. Given its psycho-affective properties of
inducing euphoria, disinhibition and sexual arousal, the
drug was later used as an adjunct to psychotherapy. In
the 1980s, MDMA became a trendy drug of abuse, par-
ticularly at rave parties and dance clubs. However, its
potential for abuse was soon recognized, thus prompting
government officials to place restrictions on its use [3].
In Brazil, the first shipments of ecstasy arrived in São
Paulo in 1994, mainly from Amsterdam, and began to
be trafficked, mostly at raves and dance clubs [4].
Ecstasy is mistakenly seen by young people as a ‘safe’
drug compared with amphetamines. However, it not
only has some of the toxicity of amphetamines but also
other detrimental acute effects (including increased risk
of fatal arrhythmias, rhabdomyolysis, acute kidney fail-
ure, hyponatremia) and chronic effects (such as persis-
tent panic disorder symptoms, depression, insomnia and
memory impairment) [5].
We describe ecstasy use in a young woman with type
1 diabetes mellitus (T1DM) with underlying poor con-
trol who developed diabetic ketoacidosis.
Case presentation
A 19-year-old single diabetic Caucasian woman had
been on 52 units of NPH insulin (30 units in the morn-
ing and 22 at bedtime) and 12 units of regular insulin
(four units before meals) daily for six years. She pre-
sented at the emergency department with nausea, vomit-
ing and malaise of a two hour duration, after ingesting
half a tablet of ecstasy. She reported having danced
strenuously and drunk approximately 4L of mineral
water after using the drug. Polyuria, polydipsia and
altered capillary glycemia values had been present for
approximately one month, but were overlooked by the
patient. She denied fever, dysuria, coughing or irregular-
ity in the administration of insulin, but had noticed
slight urine turbidity over the preceding 15 days. She
denied having used ecstasy in association with alcohol,
or any other combination, and claimed that this had
been her first experience of using any illicit drug. She
had been admitted to another hospital three months
earlier for signs and symptoms of diabetic ketoacidosis
of unknown origin. Her last HbA1 c was 12%. On
admission, she presented with acetone breath and was
dehydrated, tachycardic, tachypneic, normotensive and
confused.
The physical examination was unremarkable, except
for a mild diffuse abdominal pain with no signs of* Correspondence: barbaravsouza@yahoo.com.br
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peritoneal irritation. Her temperature was 37.3°C and
the chest X-ray was normal. Urine analysis showed pro-
nounced ketonuria and an absence of pyuria; a urinary
bacterioscopy did not reveal bacteria; arterial blood gas
measurement revealed clinically important metabolic
acidosis (Table 1); and lactate was in the normal refer-
ence range.
The patient received immediate intravenous rehydra-
tion, regular insulin using a continuous infusion pump
and potassium replacement. She progressed with marked
improvement in the symtomatology after 24 hours. She
was discharged from hospital three days after diagnosis
and prescribed 48 units of NPH insulin daily.
Discussion
Ecstasy is one of the few drugs with dual classification:
it falls among the stimulants and the hallucinogens and
is sometimes classified as a hallucinogenic amphetamine
[6]. The drug acts primarily by promoting a massive
release of serotonin from the presynaptic cleft and, addi-
tionally, inhibits serotonin reuptake and increases its
levels in the postsynaptic receptors. The drug is also a
potent dopamine and noradrenaline releasing agent [7].
Typically, users ingest at least one tablet of ecstasy with
doses ranging between 50 mg and 200 mg, although it is
often mixed with other substances [8]. The drug is read-
ily absorbed by the gastrointestinal tract, with peak
action two to four hours after ingestion and a half-life
of approximately nine hours [4].
The acute effects of ecstasy include: a feeling of
improvement in interpersonal skills: loquacity; an
enhanced perception of music; a reduction in fatigue; a
heightened alertness; a sense of increased physical and
mental powers; and euphoria. The drug produces phy-
siological alterations such as: hyperthermia; acute sym-
pathomimetic effects (elevated heart rate and arterial
blood pressure); exacerbation of anxiety; and activation
of the hypothalamic-pituitary-adrenal axis. The most
frequently reported side effects are arrhythmias,
hyperthermia, kidney failure, seizures and intracranial
hemorrhage [9].
It is important to note that ecstasy promotes an
increased antidiuretic hormone release, which may lead
to symptomatic hyponatremia and hypo-osmolarity.
Other factors contributing to hyponatremia include psy-
chogenic polydipsia and volume depletion by loss of free
water. Thus, excess water intake could eventually
become dangerous, even fatal, since it could lead to sei-
zures, herniation and cerebral edema [10]. The woman
in our case had normal serum sodium levels on admis-
sion to hospital.
One of the most remarkable acute effects of ecstasy is
a pronounced increase in body temperature of up to
above 42°C. Hyperthermia can result from the effects of
the drug on the central nervous system, prolonged exer-
tion (for example, dancing strenuously during a rave
night) and environment conditions (crowds or hot
environments). Both the stimulant effect of ampheta-
mines and serotonin syndrome can contribute to severe
hyperthermia which may cause dehydration, dissemi-
nated intravascular coagulation, seizures and even rhab-
domyolysis [3]. A large number of ecstasy deaths are
thought to be directly or indirectly related to the effects
of hyperthermia.
The increase in body temperature, in conjunction with
the strenuous exercise of vigorous dancing, makes
drinking water a necessity for the ecstasy user [4].
Although our patient had taken a small dose of the drug
along with the compulsive intake of 4L of water
throughout the night, she had difficulty in achieving full
water-electrolyte replacement which was evident in her
case as she was severely dehydrated. This, in conjunc-
tion with hyperglycemia, metabolic acidosis and keto-
nuria, was strongly suggestive of diabetic ketoacidosis.
Seymor and colleagues reported two cases of diabetic
ketoacidosis complicated by ecstasy use. Both were insu-
lin-dependent diabetics and ingested ecstasy during a
rave party, during which they danced strenuously. They
showed good clinical evolution after fluid replacement
and the administration of insulin, although one of the
patients developed bronchopneumonia and needed intu-
bation and mechanical ventilation [11].
Lee and colleagues conducted a study with patients
who had type-1 diabetes mellitus, assessing the impact
of substances of abuse on the level of acidosis of the
diabetic ketoacidosis. Of the 19 patients evaluated, six
had used ecstasy. Drug users were found to develop
more severe acidosis than non-users of illicit substances
[12].
A study by De Micheli and colleagues had a sample of
6417 students and showed that the prevalence of young
Table 1 Laboratory tests
Tests Admission Discharge
Hematocrit/hemoglobin 42.5%/13.7 g/dL 35.9%/12.6 g/dL
White blood cells 23.100/mm3 4.460/mm3
Neutrophils 18.480/mm3 2.720/mm3
Sodium 138 mmol/L 137 mmol/L
Potassium 5.4 mmol/L 3.3 mmol/L
Serum glucose 540 mg/dL 124 mg/dL
Urea/creatinine 42/1.2 mg/dL 23/0.82 mg/dL
Gasometry
pH 7. 123 7. 535
Bicarbonate 2.5 mmol/L 20.7 mmol/L
Chloride 110 mEq/L 98 mEq/L
Anion gap 30.9 21.6
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people who have already tried drugs of abuse is high in
secondary schools in the interior of the state of São
Paulo; only 0.9% had already consumed ecstasy. The
average age at the time of the first experience with
ecstasy is 20 years - ranging between 13 and 41 years.
The pattern of ecstasy use in Brazil comprises young
men who are: polydrug users; heterosexual; single; have
a college degree or some college education; and belong
to the upper socioeconomic classes. This is a drug use
pattern similar to that seen in other countries [13].
A survey conducted with Brazilian users found that ‘a
concern with physical health’ is the most influential fac-
tor in the frequency of ecstasy use. However, only a
minority of users wanted to reduce the use or discon-
tinue using the drug [14].
The association between decompensated diabetes and
the use of illicit drugs is frequent. Some authors see
poor control of diabetes as a possible warning sign for
the likelihood of a young person becoming involved
with illicit drugs. Adolescents are most vulnerable to
drug abuse and often ignore warnings about the danger
of using such drugs means there is an increased risk of
death among this age group [10]. This risk should,
therefore, be addressed in all medical interviews with
adolescents.
Conclusion
The use of ecstasy may trigger diabetic ketoacidosis in
patients with a preexisting metabolic disorder. This is
demonstrated in the present case and other cases
described in the published literature. The strenuous
exertion often associated with the use of this drug may
compound the problem. Often patients do not wish to
discontinue ecstasy use, despite their being made aware
of the potential risk of this drug. The woman in our
case was not aware of the side effects of ecstasy. We
believe that improved screening and diagnosis, as well
as education on the seriousness of the use of illicit
drugs, are needed both by all young people but espe-
cially those who are prone to developing metabolic
disorders, such as diabetics.
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